Search Results for "amyloidosis"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
Insights from the phase 3 HELIOS-A study of vutrisiran in patients with hATTR-PN
This deck highlights data from the phase 3 HELIOS-A trial, including exploratory cardiac endpoints and post-hoc analyses.
This deck highlights data from the phase 3 HELIOS-A trial, including exploratory cardiac endpoints and post-hoc analyses.
Screening, Recognition, and Barriers to Diagnosis of ATTR
This deck highlights the screening, recognition, and barriers of diagnosis in ATTR.
This deck highlights the screening, recognition, and barriers of diagnosis in ATTR.
Diagnosis of ATTR
This deck highlights the red flag symptoms of ATTR and the tools to help achieve an accurate diagnosis.
This deck highlights the red flag symptoms of ATTR and the tools to help achieve an accurate diagnosis.
Symptoms and Disease Burden of ATTR
This slide deck provides an overview of the symptoms and disease burden of ATTR.
This slide deck provides an overview of the symptoms and disease burden of ATTR.
